What lies ahead for the BK virus infection market by 2034?

Emerging therapies are anticipated to drive its growth.

The global polyomavirus (BK Virus) infection market is expected to see a surge in growth with its dynamics projected to change until 2034, according to a DelveInsight analysis.

The report revealed that this expansion is attributed to increased awareness and advancements in diagnostic technologies whilst being driven by a rise in kidney transplant procedures and the subsequent need for effective treatments and management in immunocompromised patients.

“BKV infections generally occur in patients, who undergo transplantation or surgical procedures. Viral infections after renal transplantation have emerged as an important cause of allograft loss,” the report said.

Meanwhile, emerging therapies are anticipated to further drive the market’s growth for its potential benefits such as improved efficacy and improved diagnosis.

This is accompanied by an increase in research and development activities to advance treatment options, with organisations working to provide information on this disorder.

“Although current treatment options for BKV infection are very few, this opens a platform for new therapies to boost the market,” it added.